SCHEMBL5134953

SCHEMBL5134953

CCCCN(Cc1ccc(O)cc1Cl)C(C)c1cnc(-c2cccc(F)c2)n1CCCC

nearest known ligand 0.36

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
S1PR1 P21453 3/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
GCGR P47871 1/20 0.32
P2RX7 Q99572 2/20 0.31
ESR1 P03372 1/20 0.31
TRPM8 Q7Z2W7 1/20 0.30
PPARD Q03181 2/20 0.30
ICMT O60725 1/20 0.30
GRIN2B Q13224 1/20 0.30
PPARA Q07869 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136610 0.94 MEN1 (0.36) MEN1KMT2AS1PR1MAOAMAOB
SCHEMBL5136271 0.92 MEN1 (0.37) MEN1KMT2AMAOAMAOBP2RX7
SCHEMBL5136275 0.87 MEN1 (0.38) MEN1KMT2AS1PR1GCGRP2RX7
SCHEMBL5134757 0.82 ICMT (0.35) MEN1KMT2AS1PR1P2RX7ESR1
SCHEMBL5073855 0.81 TSHR (0.36) MEN1KMT2AESR1
SCHEMBL5134901 0.81 MEN1 (0.37) MEN1KMT2AMAOAMAOBGCGR
SCHEMBL5137587 0.79 PDK1 (0.36) MEN1KMT2AMAOBP2RX7ICMT
SCHEMBL5136213 0.77 C5AR1 (0.50)
SCHEMBL5072274 0.76 TSHR (0.35) MEN1KMT2AESR1
SCHEMBL4770835 0.74 TSHR (0.39) MEN1KMT2AESR1ICMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed